Recurrent neurosurgical site infection by extensively drug-resistant <i>P. aeruginosa</i> treated with cefiderocol: a case report and literature review

Bavaro, Davide Fiore; Romanelli, Federica; Stolfa, Stefania; Belati, Alessandra; Diella, Lucia; Ronga, Luigi; Fico, C; Monno, Laura; Saracino, Annalisa

doi:10.1080/23744235.2020.1856921

Cited by 18 publications

(33 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We identified 30 case reports and case series including 78 patients who had recalcitrant infections caused by MDR Gram-negative bacteria, and treated with salvage treatment or compassionate use of cefiderocol in real-world settings ( Edgeworth et al, 2019 ; Stevens and Clancy, 2019 ; Trecarichi et al, 2019 ; Alamarat et al, 2020 ; Contreras et al, 2020 ; Dagher et al, 2020 ; Kufel et al, 2020 ; Lampejo et al, 2020 ; Oliva et al, 2020 ; Siméon et al, 2020 ; Zingg et al, 2020 ; Bavaro et al, 2021a ; Bavaro et al, 2021b ; Bleibtreu et al, 2021 ; Bodro et al, 2021 ; Borghesi et al, 2021 ; Carney et al, 2021 ; Chavda et al, 2021 ; Cipko et al, 2021 ; Falcone et al, 2021 ; Fratoni et al, 2021 ; Grande Perez et al, 2021 ; Grasa et al, 2021 ; Klein et al, 2021 ; König et al, 2021 ; Mabayoje et al, 2021 ; Martinez et al, 2021 ; Mc Gann et al, 2021 ; Warner et al, 2021 ; Zaidan et al, 2021 ). The detailed characteristics of these cases are summarized in Supplementary Table S3 .…”

Section: Resultsmentioning

confidence: 99%

Cefiderocol for the Treatment of Multidrug-Resistant Gram-Negative Bacteria: A Systematic Review of Currently Available Evidence

et al. 2022

View full text Add to dashboard Cite

Cefiderocol is a novel synthetic siderophore-conjugated antibiotic that hijacks the bacterial iron transport systems facilitating drug entry into cells, achieving high periplasmic concentrations. This systematic review analyzed the currently available literature on cefiderocol. It summarized in vitro susceptibility data, in vivo antimicrobial activity, pharmacokinetics/pharmacodynamics (PK/PD), clinical efficacy, safety and resistance mechanisms of cefiderocol. Cefiderocol has potent in vitro and in vivo activity against multidrug-resistant (MDR) Gram-negative bacteria, including carbapenem-resistant isolates. But New Delhi Metallo-β-lactamase (NDM)- positive isolates showed significantly higher MICs than other carbapenemase-producing Enterobacterales, with a susceptible rate of 83.4% for cefiderocol. Cefiderocol is well-tolerated, and the PK/PD target values can be achieved using a standard dose regimen or adjusted doses according to renal function. Clinical trials demonstrated that cefiderocol was non-inferiority to the comparator drugs in treating complicated urinary tract infection and nosocomial pneumonia. Case reports and series showed that cefiderocol was a promising therapeutic agent in carbapenem-resistant infections. However, resistant isolates and reduced susceptibility during treatment to cefiderocol have already been reported. In conclusion, cefiderocol is a promising powerful weapon for treating MDR recalcitrant infections.

show abstract

Section: Resultsmentioning

confidence: 99%

Cefiderocol for the Treatment of Multidrug-Resistant Gram-Negative Bacteria: A Systematic Review of Currently Available Evidence

et al. 2022

View full text Add to dashboard Cite

show abstract

“…With the exception of the three randomized non-inferiority clinical trials (the CREDIBLE-CR [11], the APEKS-NP [12] and the APEKS-cUTI [13]), only a few case reports and small case series described the use of cefiderocol in real-life settings [14][15][16], showing encouraging results. Accordingly, the aim of this study is to provide a description of our compassionate use clinical experience, and discuss possible future perspective of this new molecule in the treatment of severe infections in critically ill and immunocompromised hosts.…”

Section: Introductionmentioning

confidence: 99%

Cefiderocol-Based Combination Therapy for “Difficult-to-Treat” Gram-Negative Severe Infections: Real-Life Case Series and Future Perspectives

et al. 2021

Self Cite

View full text Add to dashboard Cite

Cefiderocol is a new cephalosporin displaying against extensively resistant (XDR) Gram-negative bacteria. We report our experience with cefiderocol-based combination therapies as “rescue” treatments in immunocompromised or critically ill patients or in patients with post-surgical infections who had failed previous regimens. A total of 13 patients were treated from 1 September 2020 to 31 March 2021. In total, 5/13 (38%) patients were classified as critically ill, due to severe COVID-19 lung failure; 4/13 (31%) patients had post-surgical infections and 4/13 (31%) had severe infections in immunocompromised subjects due to solid organ transplantation (2/4) or hematological malignancy (2/4). Overall, 10/13 infections were caused by carbapenem-resistant Acinetobacter baumannii, one by KPC-positive ceftazidime/avibactam-resistant Klebsiella pneumonia and two by Pseudomonas aeruginosa XDR. Based on clinical, microbiological and hematobiochemical evaluation, cefiderocol was associated with different companion drugs, particularly with fosfomycin, high-dose tigecycline and/or colistin. Microbiological eradication was achieved in all cases and the 30-day survival rate was 10/13; two patients died due to SARS-CoV-2 lung failure, whereas one death was attributed to subsequent infections. No recurrent infections within 30 days were reported. Finally, we hereby discuss the therapeutic potential of cefiderocol and the possible place in the therapy of this novel drug.

show abstract

“…Among the 27 studies were 18 (66.7%) case reports, [19][20][21][22][23][24][25][26][27][28][29][30][31][32][33][34][35][36] eight (29.6%) case series, [11][12][13][14][15][16][17][18] and one (3.7%) phase 3 clinical trial Table 1. 10 Across the studies, 76 patients were included.…”

Section: Summary Of Included Studiesmentioning

confidence: 99%

“…Bacteremia/sepsis was reported in 51 (67.1%) patients, 10,11,[13][14][15][16][17]24,29,30,32,36 most commonly with an unidentified infection (n = 10, 19.6%), 10,11,14,15 intra-abdominal infection (n = 8, 15.7%), 10,13,24,30 or intravenous line/catheter-associated source (n = 8, 15.7%). 10,11 The second and third most common infections were bone and joint infections (BJI) (n = 13, 17.1%) 12,16,[18][19][20][21][22][23]25,33,34 and CF exacerbations (n = 9, 11.8%). 17,27 Among the 76 patients, A. baumannii was identified in 32 (42.1%) patients, [10][11][12]14,16,18,23,25,33 P. aeruginosa was identified in 18 (23.7%) patients, [10][11][12][13]…”

Section: Summary Of Included Studiesmentioning

confidence: 99%

Safety and efficacy of cefiderocol for off‐label treatment indications: A systematic review

et al. 2022

View full text Add to dashboard Cite

Purpose Cefiderocol is a siderophore cephalosporin recently approved by the United States Food and Drug Administration for the treatment of hospital‐ and ventilator‐acquired bacterial pneumonia and complicated urinary tract infections. However, there is potential for cefiderocol utility for a variety of other infections. The purpose of this systematic review was to identify literature examining the safety and efficacy of cefiderocol for off‐label indications. Methods The PRISMA guidelines were utilized for reporting. Databases searched included PubMed, Scopus, and Embase, from inception to September 2021. Manuscripts describing cefiderocol off‐label use in clinical settings were included. Exclusion criteria were studies focused on labeled indications, animal studies, pharmacodynamic/pharmacokinetic studies, in vitro or laboratory studies, and manuscripts in languages other than English or Arabic. Each stage of review utilized two independent investigators, with conflicts resolved and critical appraisal performed. Data regarding presentation, clinical course, and infection characteristics were extracted and descriptively analyzed. Results The search identified a total of 985 records, narrowed to a final set of 27 studies. Among studies included were 18 (66.7%) case reports, 8 (29.6%) case series, and 1 (3.7%) phase 3 clinical trial. Cefiderocol was most frequently used off‐label for bacteremia/sepsis with or without an identified source in 51 (67.1%) out of a total of 76 included patients. Among case series/reports with available data, 43 of 53 patients (81.1%) received combination antibiotic therapy. The most common pathogens identified included multi/extensively drug‐resistant Pseudomonas aeruginosa and/or Acinetobacter baumannii. Various clinical end points were reported, while microbiological end points were reported in 18 (66.7%) studies. Cefiderocol‐related side effects were uncommon and rarely use‐limiting. Conclusions This systematic review depicts relative clinical effectiveness of off‐label cefiderocol, most commonly for P. aeruginosa and A. baumannii infections as combination antibiotic therapy. Further study is needed to elucidate the safety and efficacy of cefiderocol across an expanded set of patients and indications.

show abstract

Recurrent neurosurgical site infection by extensively drug-resistant P. aeruginosa treated with cefiderocol: a case report and literature review

Cited by 18 publications

References 16 publications

Cefiderocol for the Treatment of Multidrug-Resistant Gram-Negative Bacteria: A Systematic Review of Currently Available Evidence

Cefiderocol for the Treatment of Multidrug-Resistant Gram-Negative Bacteria: A Systematic Review of Currently Available Evidence

Cefiderocol-Based Combination Therapy for “Difficult-to-Treat” Gram-Negative Severe Infections: Real-Life Case Series and Future Perspectives

Safety and efficacy of cefiderocol for off‐label treatment indications: A systematic review

Contact Info

Product

Resources

About